Li Ka-Shing Backs Asia’s First Kidney Cancer Trial of Ultrasound Treatment
00:00/00:00
Listen to this article
1x
Subscribe now
Listen to the full version
Listen to the full version
Histotripsy inventor Xu Zhen receives the 2026 Golden Goose Award from the American Association for the Advancement of Science (AAAS) for translating long-term basic scientific research into practical medical applications.
A non-invasive ultrasound technology that destroys tumors without incisions is expanding to new cancer types, as Hong Kong prepares to become the first city in Asia to conduct clinical trials of the treatment on kidney cancer.
The Li Ka-shing Foundation announced Monday that it will push histotripsy applications into renal cancer trials, with Li Ka-shing funding 30 spots for the procedure.
You've accessed an article available only to subscribers
VIEW OPTIONS
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Subscribe to both Caixin Global and Bloomberg - for the price of one.
Share this article
Open WeChat and scan the QR code
Sign in with Google
Sign in with Facebook
Sign in with 财新